Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.36 USD | -1.40% | -7.58% | +68.73% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.73% | 1.49B | |
+7.64% | 115B | |
+12.74% | 107B | |
-13.27% | 22.31B | |
-3.99% | 21.6B | |
-6.19% | 18.23B | |
-39.93% | 17.62B | |
+6.85% | 14.26B | |
+32.78% | 12.37B | |
-28.20% | 8.28B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy